Atossa Genetics Inc. Aktie News

SEATTLE, 7. Aug. 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa oder das Unternehmen), ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien in der Onkologie und in anderen Bereichen mit hohem ungedecktem medizinischen Bedarf entwickelt, gab heute seine Finanzergebnisse bekannt und lieferte ein Update zu den jüngsten Unternehmensentwicklungen ...

Peer-reviewte präklinische Studie in npj Breast Cancer identifiziert neue chemische Verbindungen mit Aktivität in ESR1-mutanten Modellen. Ergebnisse deuten auf Potenzial für Kombination mit abemaciclib hin. SEATTLE, 28. Juli 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" oder das "Unternehmen"), ein im klinischen Stadium befindliches biopharmazeutisches Unternehmen, das...

Präklinisches Poster hebt duale Modulation von Östrogenrezeptor und PKC-β/AKT-Weg als potenzielle therapeutische Strategie bei östrogengetriebener Pathologie im McCune-Albright-Syndrom hervor SEATTLE, July 21, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) ("Atossa" oder das "Unternehmen"), ein biopharmazeutisches Unternehmen im klinischen Stadium, das neuartige Therapien in der ...

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 12, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced the closing of ...

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrants SEATTLE, June 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced that it has ent...

Preclinical Data Abstract Demonstrates Robust Estrogen Receptor (ER) Inhibition in ESR1-Mutant Breast Cancer Models at Clinically Relevant Concentrations Trial-in-Progress Abstract Details Ongoing Phase 2 EVANGELINE Study of (Z)-Endoxifen Plus Goserelin as Neoadjuvant Therapy in Premenopausal Women With ER+/HER2- Breast Cancer SEATTLE, May 27, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nas...

Review article accepted for publication in Degenerative Neurological and Neuromuscular Disease and builds on Atossa's previously published Duchenne Muscular Dystrophy (DMD) research SEATTLE, May 20, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significan...

Event to feature Dr. Laura Esserman, internationally recognized surgical oncologist, breast cancer expert, and founder and principal investigator of the I-SPY Trials SEATTLE, May 14, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of significant unmet medi...